Terms: = Liver cancer AND CBFA2T3, ETO2, 863, ENSG00000129993, ZMYND4, MTGR2, MTG16 AND Treatment
39 results:
1. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
Ji J; Zhang Z; Hou Z; Qiu G; Mi S; Jin Z; Huang J
Clin Res Hepatol Gastroenterol; 2024 Apr; 48(4):102313. PubMed ID: 38453011
[TBL] [Abstract] [Full Text] [Related]
2. Application of the Left Lateral Decubitus Position in Laparoscopic Right Posterior Lobectomy.
Huang DF; Xu JB; Du YM; Wang YB; Zhou DH
Surg Laparosc Endosc Percutan Tech; 2024 Apr; 34(2):178-184. PubMed ID: 38417113
[TBL] [Abstract] [Full Text] [Related]
3. TBACkp: HER2 expression status classification network focusing on intrinsic subenvironmental characteristics of breast cancer liver metastases.
Yang K; Song J; Liu M; Xue L; Liu S; Yin X; Liu K
Comput Biol Med; 2024 Mar; 170():108002. PubMed ID: 38277921
[TBL] [Abstract] [Full Text] [Related]
4. Intratumoral and peritumoral radiomics based on contrast-enhanced MRI for preoperatively predicting treatment response of transarterial chemoembolization in hepatocellular carcinoma.
Zhao Y; Zhang J; Wang N; Xu Q; Liu Y; Liu J; Zhang Q; Zhang X; Chen A; Chen L; Sheng L; Song Q; Wang F; Guo Y; Liu A
BMC Cancer; 2023 Oct; 23(1):1026. PubMed ID: 37875815
[TBL] [Abstract] [Full Text] [Related]
5. Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma.
Zou H; Xue Y; Chen X; Lai Y; Yao D; Ung COL; Hu H
PLoS One; 2023; 18(10):e0292239. PubMed ID: 37796814
[TBL] [Abstract] [Full Text] [Related]
6. Development and validation of a model to predict the risk of distant metastases from hepatocellular carcinoma: a real-world retrospective study.
Shao G; Fan Z; Qiu W; Lv G
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16489-16499. PubMed ID: 37712961
[TBL] [Abstract] [Full Text] [Related]
7. Survival Benefit Relative to treatment Modalities Among Patients with Very Early Intrahepatic Cholangiocarcinoma: an Analysis of the National cancer Database.
Endo Y; Sasaki K; Munir MM; Woldesenbet S; Resende V; Rawicz-Pruszyński K; Waqar U; Mavani P; Katayama E; Yang J; Khalil M; Khan MMM; Kitago M; Pawlik TM
J Gastrointest Surg; 2023 Oct; 27(10):2103-2113. PubMed ID: 37674099
[TBL] [Abstract] [Full Text] [Related]
8. Epidemiology and survival outcomes of synchronous and metachronous brain metastases: a retrospective population-based study.
Jiang K; Parker M; Materi J; Azad TD; Kamson DO; Kleinberg L; Ye X; Rincon-Torroella J; Bettegowda C
Neurosurg Focus; 2023 Aug; 55(2):E3. PubMed ID: 37527669
[TBL] [Abstract] [Full Text] [Related]
9. liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
[TBL] [Abstract] [Full Text] [Related]
10. Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma.
Gong XQ; Liu N; Tao YY; Li L; Li ZM; Yang L; Zhang XM
Sci Rep; 2023 May; 13(1):7710. PubMed ID: 37173350
[TBL] [Abstract] [Full Text] [Related]
11. Disparities in the Receipt of Recommended Curative treatment for Patients with Early-Stage Hepatocellular Carcinoma.
Rasic G; de Geus SWL; Papageorge MV; Woods AP; Ng SC; McAneny D; Tseng JF; Sachs TE
World J Surg; 2023 Jul; 47(7):1780-1789. PubMed ID: 36918443
[TBL] [Abstract] [Full Text] [Related]
12. Influence of Child-Pugh B7 and B8/9 cirrhosis on laparoscopic liver resection for hepatocellular carcinoma: a retrospective cohort study.
Watanabe Y; Aikawa M; Kato T; Takase K; Watanabe Y; Okada K; Okamoto K; Koyama I
Surg Endosc; 2023 Feb; 37(2):1316-1333. PubMed ID: 36203111
[TBL] [Abstract] [Full Text] [Related]
13. Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy.
Wrenger R; Jüptner M; Marx M; Zhao Y; Zuhayra M; Caliebe A; Osmonov D; Lützen U
BMC Urol; 2022 Jul; 22(1):96. PubMed ID: 35788220
[TBL] [Abstract] [Full Text] [Related]
14. Simultaneous versus staged major hepatectomy (≥3 liver segments) for outcomes of synchronous colorectal liver metastases: A systematic review and meta-analysis.
Liu J; Xia Y; Pan X; Yan Z; Zhang L; Yang Z; Wu Y; Xue H; Bai S; Shen F; Wang K
Cancer Rep (Hoboken); 2022 Aug; 5(8):e1617. PubMed ID: 35753719
[TBL] [Abstract] [Full Text] [Related]
15. Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment.
Huang X; Wang H; Zhang W; Gu E
Eur J Gastroenterol Hepatol; 2022 May; 34(5):546-552. PubMed ID: 35170528
[TBL] [Abstract] [Full Text] [Related]
16. In Vitro and In Vivo Evaluation of SP94 Modified Liposomes Loaded with N-14NCTDA, a Norcantharimide Derivative for Hepatocellular Carcinoma-Targeting.
Jiang Y; Liu X; Tan X; Hou Y; Sun W; Gou J; Yin T; He H; Zhang Y; Tang X
AAPS PharmSciTech; 2020 Oct; 21(7):277. PubMed ID: 33033942
[TBL] [Abstract] [Full Text] [Related]
17. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
Tseng CH; Hsu YC; Chen TH; Ji F; Chen IS; Tsai YN; Hai H; Thuy LTT; Hosaka T; Sezaki H; Borghi JA; Cheung R; Enomoto M; Nguyen MH
Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1039-1052. PubMed ID: 33007228
[TBL] [Abstract] [Full Text] [Related]
18. Effect of surgical delay on survival outcomes in patients undergoing curative resection for primary hepatocellular carcinoma: Inverse probability of treatment weighting using propensity scores and propensity score adjustment.
Kabir T; Syn N; Ramkumar M; Yeo EYJ; Teo JY; Koh YX; Lee SY; Cheow PC; Chow PKH; Chung AYF; Ooi LL; Chan CY; Goh BKP
Surgery; 2020 Feb; 167(2):417-424. PubMed ID: 31677800
[TBL] [Abstract] [Full Text] [Related]
19. Hepatocellular carcinoma: Impact of academic setting and hospital volume on patient survival.
Uhlig J; Sellers CM; Khan SA; Cha C; Kim HS
Surg Oncol; 2019 Dec; 31():111-118. PubMed ID: 31654956
[TBL] [Abstract] [Full Text] [Related]
20. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
Bracarda S; Bamias A; Casper J; Negrier S; Sella A; Staehler M; Tarazi J; Felici A; Rosbrook B; Jardinaud-Lopez M; Escudier B
Clin Genitourin Cancer; 2019 Jun; 17(3):e689-e703. PubMed ID: 31072748
[TBL] [Abstract] [Full Text] [Related]
[Next]
